Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Diaz

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Journal for Immunotherapy of Cancer|April 28, 2025
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A Ahmed, Younchul Kim, Sungjune Kim, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.
Pigment Cell & Melanoma Research|May 27, 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.
Cancer Communications (London, England)|March 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma CohortJavier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, et al.
Nature Medicine|February 6, 2024
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial resultsSergio Crespo-Garcia, Frédérik Fournier, Roberto Diaz-Marin, et al.
Science (New York, N.Y.)|August 22, 2020
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathyFrançois Binet, Gael Cagnone, Sergio Crespo-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled TrialMrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Journal for Immunotherapy of Cancer|April 28, 2025
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A Ahmed, Younchul Kim, Sungjune Kim, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.
Pigment Cell & Melanoma Research|May 27, 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.
Cancer Communications (London, England)|March 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma CohortJavier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, et al.
Nature Medicine|February 6, 2024
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial resultsSergio Crespo-Garcia, Frédérik Fournier, Roberto Diaz-Marin, et al.
Science (New York, N.Y.)|August 22, 2020
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathyFrançois Binet, Gael Cagnone, Sergio Crespo-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled TrialMrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, et al.
Pageof 12